Compare Ascendis Pharma A/S (ASND) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Estee Lauder Companies Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Estee Lauder Companies Inc trades at $82.6 (market cap $29.91B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.69% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EL | |
|---|---|---|
Market Cap | $17.74B | $29.91B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $119.61 |
52-Week Low | $163.32 | $67.23 |
Enterprise Value | $18.11B | $36.08B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Estée Lauder (EL) trades at $82.66, up 0.82% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported negative net income of -$1.13B in 2025, though it has beaten EPS estimates in recent quarters. Revenue has declined from $17.7B in 2022 to $14.33B in 2025, while debt-to-asset ratio rose to 36.78%.
The outlook is mixed: analyst consensus is a Buy with a $90.60 price target, but high valuation ratios and profitability challenges pose risks. Positive sentiment from news highlights innovation and industry trends, yet financial performance and macroeconomic pressures remain headwinds for near-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
